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Abstract
The prognostic value of detection of
human papillomavirus (HPV) type 16
DNA in histologically cancer free lymph
nodes was assessed in left obturator lymph
nodes from cervical cancer patients with
HPV-16 positive primary tumours.
HPV-16 DNA was detected by polymerase
chain reaction in 12 of 35 patients with
histologically cancer free lymph nodes. Of
these 12 patients, only one developed a
recurrence, suggesting HPV-16 DNA de-
tection in cancer free lymph nodes has no
prognostic value.
(7 Clin Pathol 1997;50:960-96 1)
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The association between the presence ofhuman
papillomavirus (HPV) DNA and cervical carci-
noma has been established beyond doubt.'
Presence or absence of pelvic lymph node
involvement is one of the strongest predictive
factors for prognosis in patients with cervical
cancer.' A number of studies has investigated
the presence of HPV DNA in lymph nodes
from patients with HPV DNA in their primary
tumour3-5 and found HPV DNA positivity
ranging from 14.3-50% in histologically nega-
tive lymph nodes. However, the prognostic sig-
nificance could not be established in these
reports because of lack of follow up data.
Methods
To investigate the frequency of detectable HPV
DNA in histologically cancer free lymph
nodes, we examined 50 patients with
squamous cell cervical carcinoma treated at the
department of obstetrics and gynaecology,
University Hospital Groningen (median time
of follow up was 47.5 months; range 24-132
months). The patients were staged according
to the FIGO classification as stage Ib (n = 36),
stage IIa (n = 9), or stage IIb (n = 5). All
patients were positive for HPV type 16 in their
primary tumour. From these patients paraffin
wax embedded tissue of the left obturator
lymph nodes (one node for each patient) was
investigated. (We do not think that analysis of a
single obturator lymph node would introduce
bias.) All 50 obturator lymph nodes examined
were histologically negative for tumour cells.
However, 15 patients had histological evidence
of metastasis to one or more other lymph
nodes.
DNA was extracted from 10 gm sections by
deparaffination and digestion with proteinase K
as described by Wright and Manos.6 Adjacent
sections were stained with haematoxylin and
eosin. As a control for DNA extraction P globin
primers PC03/04 (ACACAACTGTGT-
TCACTAGC and CAACTTCATCCACGT-
TCACC) were used. For detection of HPV-16
DNA a primer pair (GGTCGGTGGACCG-
GTCGATG and GCAATGTAGGTGTAT-
CTCCA) described in Baay et al,7 spanning a
96 base pair DNA sequence of the E6 open
reading frame was used.
Polymerase chain reaction (PCR) amplifica-
tion was performed according to the method of
Saiki et al.' The final 100 gl PCR reaction con-
tained 10 ,ul sample, 10 mM Tris-HCl pH 9.0,
50 mM KCI, 2.5 mM MgCl,, 0.1% Triton
X100, 0.01% gelatin, 200,M dNTPs,
50 pmol of each primer, and 0.25 units of
SuperTaq (Sphaero Q, Cambridge, UK).
Standard PCR conditions were one minute at
95°C, one minute at 52°C, and two minutes at
72°C, for 40 cycles. After PCR, 15,l of all
samples were run on a 2% agarose gel, gels
were blotted (Hybond N+; Amersham, Little
Chalfont, UK) and hybridised with random
labelled HPV-16 E6. Blots were washed twice
for 15 minutes in 2x SSC, 0.1% SDS at 420C.
Results
All obturator lymph nodes were positive in the f
globin PCR (100 base pair DNA fragment).
Nineteen (38%) of the obturator lymph nodes
were positive for HPV-16 DNA. HPV-16 DNA
was detected in seven of 15 patients (46.6%)
with known lymph node involvement elsewhere,
compared with 12 of 35 patients (34.3%) with-
out histological evidence for lymph node in-
volvement. Therefore, no difference was found
between these groups of patients with regard to
the frequency of HPV-16 DNA (p = 0.61; x2
test with Yates' correction). Furthermore, there
was no significant difference in staging between
patients with HPV positive cancer free lymph
nodes (Ib, n = 10, IIa, n = 2), and patients with
HPV negative cancer free lymph nodes (Ib,
n = 19, IIa, n = 4).
Discussion
In approximately one-third (12 of 35) of the
patients without histological evidence for
lymph node involvement, HPV-16 DNA could
be detected in the lymph node examined. This
is in accordance with data from the literature
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where HPV DNA positivity in histologically
negative lymph nodes ranging from 14.3-50%
has been reported.3-5
Burnett et al assign a prognostic value to the
detection of HPV DNA in histologically nega-
tive lymph nodes.9 This assumption has been
based on the finding that, in six patients with
recurrent disease, 22 of 31 (71 %) histologically
negative lymph nodes were positive for HPV
DNA compared with 15 of 43 (35%) histologi-
cally negative lymph nodes from six patients in
complete remission. It is not clear, however,
whether the number of HPV DNA positive
nodes in the individual patient is related to
clinical outcome.9 Nawa et al reported recur-
rence of disease in two of five patients with
cancer free lymph nodes that were positive for
HPV DNA.4 In the present study, only one of
12 patients without histological evidence for
lymph node involvement but positive for HPV
DNA developed a recurrence. All other
patients showed no evidence of disease (me-
dian time of follow up, 47.5 months; range
24-132 months). This is in accordance with
results of the study by Hording et al,10 which
showed no correlation between HPV presence
and recurrence.
In the study by Burnett et al, five of six-
patients with recurrence were positive for
HPV-18.9 This HPV type has been described as
biologically more aggressive than HPV-16.11
Therefore, it cannot be ruled out that detection
of HPV- 1 8 DNA in histologically negative
lymph nodes may be of prognostic value. The
presence of HPV DNA in histologically
negative lymph nodes may be due to subclini-
cal metastasis of tumour cells. Alternatively it
may represent DNA from tumour cells de-
stroyed by immune competent cells, either as
circulating fragments or internalised by scaven-
ger cells, such as macrophages. Possibly, detec-
tion of HPV specific mRNA might provide an
answer to this question. Unfortunately, too
little material was available to perform such an
analysis in the present study.
In conclusion, no prognostic value has been
found for the detection of HPV DNA in histo-
logically cancer free lymph nodes from patients
with HPV-1 6 positive primary tumours.
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